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Abstract
Border disease has been assessed according to the criteria of the Animal Health Law (AHL), in
particular criteria of Article 7 on disease proﬁle and impacts, Article 5 on the eligibility of Border
disease to be listed, Article 9 for the categorisation of Border disease according to disease prevention
and control rules as in Annex IV and Article 8 on the list of animal species concerned by Border
disease. The assessment has been performed following a methodology composed of information
collection and compilation, expert judgement on each criterion at individual and, if no consensus was
reached before, also at collective level. The output is composed of the categorical answer, and for the
questions where no consensus was reached, the different supporting views are reported. Details on
the methodology used for this assessment are explained in a separate opinion. According to the
assessment performed, Border disease can be considered eligible to be listed for Union intervention as
laid down in Article 5(3) of the AHL. The disease would comply with the criteria as in Sections 3, 4 and
5 of Annex IV of the AHL, for the application of the disease prevention and control rules referred to in
points (c), (d) and (e) of Article 9(1). The animal species to be listed for Border disease according to
Article 8(3) criteria are mainly sheep and other species of the family Bovidae as susceptible and
reservoirs.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
The background and Terms of Reference (ToR) as provided by the European Commission for the
present document are reported in Section 1.2 of the scientiﬁc opinion on the ad hoc methodology
followed for the assessment of the disease to be listed and categorised according to the criteria
of Article 5, Annex IV according to Article 9, and 8 within the Animal Health Law (AHL) framework
(EFSA AHAW Panel, 2017).
1.2. Interpretation of the Terms of Reference
The interpretation of the ToR is as in Section 1.2 of the scientiﬁc opinion on the ad hoc
methodology followed for the assessment of the disease to be listed and categorised according to the
criteria of Article 5, Annex IV according to Article 9, and 8 within the AHL framework (EFSA AHAW
Panel, 2017).
The present document reports the results of assessment on Border disease (BD) according to the
criteria of the AHL articles as follows:
• Article 7: Border disease proﬁle and impacts
• Article 5: eligibility of Border disease to be listed
• Article 9: categorisation of Border disease according to disease prevention and control rules as
in Annex IV
• Article 8: list of animal species related to Border disease.
2. Data and methodologies
The methodology applied in this opinion is described in detail in a dedicated document about the
ad hoc method developed for assessing any animal disease for the listing and categorisation of
diseases within the AHL framework (EFSA AHAW Panel, 2017).
3. Assessment
3.1. Assessment according to Article 7 criteria
This section presents the assessment of BD according to the Article 7 criteria of the AHL and
related parameters (see Table 2 of the opinion on methodology (EFSA AHAW Panel, 2017)), based on
the information contained in the fact-sheet as drafted by the selected disease scientist (see Section 2.1
of the scientiﬁc opinion on the ad hoc methodology) and amended by the AHAW Panel.
3.1.1. Article 7(a) Disease Proﬁle
Border disease is a pestivirus disease of mainly sheep and occasionally goats caused by border
disease virus (BDV): family Flaviviridae, genus Pestivirus (Nettleton et al., 1998; OIE, 2017). Like all
pestiviruses, BDV can infect a wide range of host species but was initially described as a pathogen of
sheep. Infection of immunocompetent animals generally leads to mild symptoms followed by
seroconversion. However, occasional isolates may cause more serious disease (Chappius et al., 1984;
OIE, 2017). Infection of females during pregnancy can lead to abortion, stillbirth, birth defects and the
birth of congenitally infected progeny. In goats, abortion is the main outcome but occasional
persistently infected (PI) kids can be born. PI lambs or kids are seronegative, tolerant of the virus and
shed it in all secretions and excretions throughout their lives, making them a major driver of BD
epidemiology. They can have ﬂeece abnormalities in addition to musculoskeletal and nervous signs.
Classical appearance is the ‘hairy shaker’ lamb where the coat is noticeably longer and ﬁner than
normal and the young has tremors that can range from mild to severe. PI lambs may be born smaller
than normal and exhibit poorer growth rates and health. They may also succumb to disease similar in
appearance to mucosal disease in cattle caused by the related pestivirus bovine viral diarrhoea virus
(BVDV), characterised by the presence of cytopathic versions of the initial infecting virus (OIE, 2017).
Infection at later stages in pregnancy (after the onset of fetal immunocompetence) generally results in
birth of virus-free offspring that are seropositive and otherwise normal, although some weak lambs
may die early in life (Barlow and Patterson, 1982; OIE, 2017).
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There is no effective vaccine for BDV, although a killed vaccine has been produced (Brun et al., 1993).
Disease control is achieved by ﬂock management and biosecurity, particularly with respect to pregnant ewes.
National eradication programmes for the related pestivirus BVDV may be inﬂuenced by BDV
infection. Although BDV infects cattle infrequently, BVDV infection of sheep is more frequent and
causes disease identical to BD. This makes appropriate diagnosis and biosecurity for BD important,
especially where it could compromise the BVDV status of in-contact cattle.
3.1.1.1. Article 7(a)(i) Animal species concerned by the disease
Susceptible animal species
It is likely that pestiviruses including BDV can infect a wide range of even-toed ungulates. This
group includes domesticated species including sheep, goats, cattle and pigs, plus wild animals such as
antelopes, camels, deer, giraffes, hippopotamuses, llamas and alpacas. BDV infection has been
demonstrated by serology or virus detection in several of these species.
Parameter 1 – Naturally susceptible wildlife species (or family/orders)
• Reindeer (Rangifer tarandus) (Becher et al., 1999, 2003; Avalos-Ramirez et al., 2001)
• Chamois (Rupicapra rupicapra) (Riekerink et al., 2005)
• Pyrenean chamois (Rupicapra pyrenaica pyrenaica) (Arnal et al., 2004)
• Mouﬂon (Ovis musimon) (Hemmatzadeh et al., 2016)
• European hare (Lepus europaeus) (Colom-Cadena et al., 2016)
• Alpine ibex (Capra ibex) (Fernandez-Aguilar et al., 2016)
Parameter 2 – Naturally susceptible domestic species (or family/orders)
• Sheep (Ovis aries) (Barlow and Patterson, 1982)
• Cattle (Bos taurus/indicus) (Becher et al., 1997)
• Goats (Capra hircus) (Nettleton et al., 1998)
• Pig (Sus scrofa) (Vilcek and Belak, 1996)
• Alpaca (Vicugna pacos) (Danuser et al., 2009)
• Llama (Lama glama) (Danuser et al., 2009)
Parameter 3 – Experimentally susceptible wildlife species (or family/orders)
There is little information on experimental infection, although evidence from BVDV suggests that
pestiviruses can infect a wide range of species.
• Pyrenean chamois (Rupicapra pyrenaica) (Martin et al., 2013)
Parameter 4 – Experimentally susceptible domestic species (or family/orders)
• Sheep (Nettleton et al., 1992)
• Goats (Løken et al., 1991)
• Cattle (Braun et al., 2015)
• Pigs (Cabezon et al., 2010a)
Reservoir animal species
Parameter 5 – Wild reservoir species (or family/orders)
No speciﬁc information is available.
Parameter 6 – Domestic reservoir species (or family/orders)
Sheep, cattle, goats and pigs can all produce PI offspring that shed virus and can act as a
persistent source of infection to in-contact animals, thus acting as reservoir species.
3.1.1.2. Article 7(a)(ii) The morbidity and mortality rates of the disease in animal
populations
Morbidity
Parameter 1 – Prevalence/Incidence
BD has a world-wide distribution with seroprevalence estimated to vary from 5% to 50% (OIE,
2017). However, relatively few prevalence studies have been done in recent years and cross-reactivity
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of serological assays between BDV and BVDV complicates analyses. Reports from Spain (Berriatua
et al., 2006; Valdazo-Gonzalez et al., 2006) suggested ﬂock prevalence of 68% and 100%; while 68%
of sheep on communal alpine pastures in Austria were BD-positive (Krametter-Froetscher et al., 2007).
The number of PI animals driving these high seroprevalence ﬁgures appears to be no more than 1%
of the at-risk population (Krametter-Froetscher et al., 2010; Schweizer and Peterhans, 2014). Similarly
high prevalence has also been reported in Pyrenean chamois (Fernandez-Sirera et al., 2012a).
While antigenic cross-reactivity with BVDV causes problems for assay speciﬁcity, the ability of sheep
to be infected with BVDV, inducing symptoms identical to BD, means that any BD analysis requires
either molecular conﬁrmation based on PI animals derived from the same outbreak, or the use of
monoclonal antibodies or virus neutralisation assays that can distinguish between BDV and BVDV
infection (Kaiser et al., 2017).
In goats, a study conducted in Italy in two herds where abortion, stillbirth and weak live kids were
caused by BDV, pestivirus antibodies were detected in 61/67 and in 38/169 goats, respectively, for the
two herds. In addition, a PI goat was found in one herd (Rosamilia et al., 2014).
Parameter 2 – Case-morbidity rate (% clinically diseased animals out of infected ones)
Experimental and natural infection of immunocompetent sheep has generally been reported to cause
inapparent or little overt disease (Nettleton et al., 1998), with a very low case-morbidity rate.
Symptoms include mild fever and inﬂammatory response followed by induction of virus-neutralising
antibodies (Barlow and Patterson, 1982). Experimental infection with different BDV strains also showed
mild clinical signs and similar weight gain (Thabti et al., 2002). However, a recent feedlot study showed
that about 55% of 36 lambs tested were infected with BDV and had 2.1 times higher risk of showing
gastrointestinal and respiratory signs of disease and a 20% reduction in growth rate compared to
uninfected lambs (Gonzalez et al., 2014). Infection of pregnant ewes results in BD-affected offspring
with the outcome of infection depending on the timing of infection and the strain of virus. Infection
before the onset of fetal immunocompetence causes approximately 50% fetal death, with surviving
lambs being PI and tolerant to the virus. PI lambs can be underweight and weak and many die at or
around weaning time and in distinctive cases show tremor and abnormal body conformation and hairy
ﬂeeces (Nettleton, online). However, a small proportion of PI sheep appears normal and can survive to
breeding age, giving birth to lambs that are always PI (Nettleton et al., 1992, 1998).
Infection occurring around mid-gestation can result in lambs showing severe nervous and skeletal
symptoms of BD (Nettleton et al., 1998). Lambs infected in late gestation can appear normal and
healthy, are born with BDV antibody and free of virus. Some of such lambs, however, can be stillborn
or weak and many die in early life (Nettleton et al., 1998).
BD can also occur in goats and, although disease in goats is rare, reproductive failure (barrenness, abortion,
stillbirth) is the main outcome of infection during pregnancy, found in over 80% of cases (Løken et al., 1991).
In two eastern China provinces, BDV infection was conﬁrmed in goat herds suffering intractable diarrhoea by
virus isolation with morbidity and mortality of about 28–37% and 10–15%, respectively (Li et al., 2013).
Mortality
Parameter 3 – Case-fatality rate
While infection of immunocompetent hosts has generally been reported to cause little overt
disease, mortality in the offspring of infected pregnant females depends on the timing of infection,
virulence of the infecting strain and the species/breed of the infected host. Case-fatality rates among
the offspring of infected pregnant ewes have been reported to be around 50% (Barlow and Patterson,
1982). There have also been reports of more severe forms of BD, with the Aveyron virus, for example,
producing outbreaks with mortality of 70% or more in sheep (Chappius et al., 1984; Vega et al., 2015)
or in Pyrenean chamois (Fernandez-Sirera et al., 2012a).
Congenitally infected lambs can grow slowly and many may die at or around weaning. Others may
survive to adulthood but deaths due to late onset disease, with apparent similarities to mucosal
disease in cattle, can also be seen. This fatal disease is associated with the appearance of a cytopathic
BDV variant, apparently derived from the infecting virus (Barlow et al., 1983; Gardiner et al., 1983;
Monies et al., 2004; Hilbe et al., 2009).
In Pyrenean chamois, infection with one BDV strain has been associated with population crashes
observed in this species since 2001 (Arnal et al., 2004). Experimental infection with this strain of virus
demonstrated almost 100% mortality in na€ıve infected chamois, conﬁrming this link (Cabezon et al.,
2010a; Fernandez-Sirera et al., 2012a; Martin et al., 2013; Beaunee et al., 2015).
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3.1.1.3. Article 7(a)(iii) The zoonotic character of the disease
Presence
Parameter 1 – Report of zoonotic human cases (anywhere)
There is no evidence of human infection with BDV.
3.1.1.4. Article 7(a)(iv) The resistance to treatments, including antimicrobial resistance
Parameter 1 – Resistant strain to any treatment even at laboratory level
No treatments against BDV infection are usually applied thus resistance to treatment is not
relevant.
3.1.1.5. Article 7(a)(v) The persistence of the disease in an animal population or the
environment
Animal population
Parameter 1 – Duration of infectious period in animals
Animals that are not previously infected in utero are viraemic for a short period (1–2 weeks) post-
infection during which time they may present a risk of infection to na€ıve in-contact animals. However,
the greatest risk of infection comes from surviving animals PI in utero. These PI animals are tolerant of
the virus, have ongoing viraemia and excrete virus in all bodily secretions. As such they are the main
source of infection for uninfected susceptible in-contact animals. Within-herd rates of infection of over
50% are common.
Parameter 2 – Presence and duration of latent infection period
There is no formal period of latent infection. Transiently infected animals have viraemia from about
day 4 after infection for about 1 week. However, PI animals, being born tolerant of the virus, are
antibody negative and virus positive and may therefore appear uninfected by serological analysis. In
addition, in PI lambs that take colostrum containing anti-BDV antibodies, the viraemia may not be
apparent for up to 2 months (OIE, 2017).
Parameter 3 – Presence and duration of the pathogen in healthy carriers
The only healthy carriers are a proportion of PI lambs that may appear healthy but carry and
excrete BDV for life (Nettleton et al., 1998; OIE, 2017).
Environment
Parameter 4 – Length of survival (dpi) of the agent and/or detection of DNA in selected matrices (soil,
water, air) from the environment (scenarios: high and low T)
BDV does not survive for long outside its host. As an enveloped virus, it is easily inactivated by
heat, drying, detergents and UV light. Recent studies suggest that enveloped viruses may survive up
to 5 days in dry environments (Firquet et al., 2015). However, where there is moisture in the
environment and temperatures are moderate (less than 15°C, for example) BDV may survive for longer
periods in agricultural environments. Direct transmission from PI to uninfected animals is considered
the main route and housing will contribute to a higher rate on infection. Spread among unhoused
grazing animals is considered to be slow (Nettleton et al., 1998), although some spread of disease
within and between species on communal alpine pasture has been reported (Krametter-Froetscher
et al., 2007; Braun et al., 2013).
3.1.1.6. Article 7(a)(vi) The routes and speed of transmission of the disease between
animals, and, when relevant, between animals and humans
Routes of transmission
Parameter 1 – Types of routes of transmission from animal to animal (horizontal, vertical)
The main mode of transmission of BDV is horizontal, via nose-to-nose contact and potentially also
via aerosols. Infection of susceptible animals in shared accommodation is highly effective compared
with open grazing (Nettleton et al., 1998; Fernandez-Sirera et al., 2012b; Nettleton, online).
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PI animals that survive to breeding age will always produce PI offspring by congenital infection of
the fetus. Vertical transmission is therefore an important factor in the epidemiology of BD because
virus shed by PI animals is the main source of infection for uninfected susceptible animals.
Parameter 2 – Types of routes of transmission between animals and humans (direct, indirect, including
food-borne)
Not applicable, since not zoonotic.
Speed of transmission
Parameter 3 – Incidence between animals and, when relevant, between animals and humans
The purchase of PI replacement females is the commonest way of introducing infection in a ﬂock,
then the transmission of BDV within ﬂocks is highly dependent on husbandry of the animals as it is
driven by the presence of PI animals and the opportunity for sheep-to-sheep contact to facilitate
infection. Spread within sheep ﬂocks that are grazed extensively is slow, potentially taking years, due to
the fragility of the virus in the environment. Spread may be much faster within housed ﬂocks or ﬂocks
sharing feeding troughs where nose-to-nose contact can occur. Sheep housed together during early
pregnancy may suffer high rates of abortion or losses due to BD at lambing (Nettleton et al., 1998).
Parameter 4 – Transmission rate (beta) (from R0 and infectious period) between animals and, when
relevant, between animals and humans
The transmission rate for BDV has not been determined. However, it is likely to be similar to that
for BVDV due similarities in their routes of infection. In experimental infection of calves, the basic
reproduction ratio (R0) was estimated to be 0.49 (95% CI 0.06; 2.99), suggesting a limited viral
spread using the BVDV-2c strain. This suggests that this BVDV-2 infection in transiently infected (TI)
animals resulted in limited transmission to other animals (Sarrazin et al., 2014).
In a previous study on a transmission model of BVD, R0 for BVDV, estimated in dairy cattle herds
without PI animals, ranged from 1.2 to 3.04, whereas this can increase up to 35.0, in the presence of
PI animals (Cherry et al., 1998). This large range reﬂects different modes of pestivirus transmission.
Vertical transmission from a PI cow is essentially 100% efﬁcient, as is contact-mediated horizontal
transmission from a PI animal. In contrast, transmission via fomites or from transiently infected
animals is less efﬁcient (Lindberg and Houe, 2005).
Transmission of BDV is driven by the presence of PI animals, which shed virus continuously for life,
and the rate of infection of other animals depends on the degree of contact possible. Thus, the
housing of pregnant na€ıve sheep with one or more PI sheep may lead to a high frequency of stillbirth,
abortion and other losses at or around lambing due to BDV infection (Nettleton et al., 1998).
3.1.1.7. Article 7(a)(vii) The absence or presence and distribution of the disease in the
Union, where the disease is not present in the Union, the risk of its introduction
into the Union
Presence and distribution
Border disease has world-wide distribution.
Parameter 1 – Map where the disease is present in EU
The Member States (MSs) were BDV infection was reported to date are Austria (Krametter-Froetscher
et al., 2007), Denmark (Tegtmeier et al., 2000), France (Dubois et al., 2008), Germany (Becher et al.,
2003), Ireland (O’Neill et al., 2004), Italy (Fernandez-Sirera et al., 2011, 2012b), the Netherlands (Orsel
et al., 2009), Slovakia (Leskova et al., 2013), Spain (Berriatua et al., 2004), Sweden (Kautto et al., 2012)
and the UK (Barlow and Patterson, 1982; Nettleton et al., 1998). Moreover, BDV infection has been
reported in Turkey (Gur, 2009), Montenegro, and Switzerland (Schaller et al., 2000; Braun et al., 2013).
BDV has also been reported outside Europe, including Australia, Japan, New Zealand, USA (Giangaspero,
2011), China (Li et al., 2013), India (Mishra et al., 2012) and Iran (Hemmatzadeh et al., 2016).
Parameter 2 – Type of epidemiological occurrence (sporadic, epidemic, endemic) at MS level
From published reports, BD has been detected in 11 EU MSs, but it is likely to be present in all MSs
where the size and density of the small ruminant population is sufﬁcient to allow maintenance of disease
circulation. Outbreaks of disease (reproductive failure, abortion, deaths of young animals) may also occur
on a seasonal basis and relate to BDV infection of pregnant animals in a previously uninfected ﬂock.
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Risk of introduction
BDV infection is already present in EU.
3.1.1.8. Article 7(a)(viii) The existence of diagnostic and disease control tools
Diagnostic tools
Parameter 1 – Existence of diagnostic tools
There is no designated OIE Reference Laboratory for BDV but most Member State laboratories that
provide pestivirus (BVDV, CSFV) testing are likely to perform BDV testing for differential diagnosis. One of
the most sensitive proven methods for identifying BDV remains virus isolation. Direct immunoﬂuorescence
or other immunohistochemical techniques on frozen tissue sections as well as antigen-detecting enzyme-
linked immunosorbent assay (ELISA) (Entrican et al., 1995) and conventional and real-time reverse-
transcription polymerase chain reaction (RT-PCR) are also valuable methods for identifying BDV-infected
animals.
Serological techniques, to identify BDV-speciﬁc antibody responses, include ELISA and virus-
neutralisation assays. Protocols for both assays are provided in the OIE chapter on BD (OIE, 2017),
while ELISA assay kits are available from a number of manufacturers, including (Table 1):
Some ELISA approaches, such as those speciﬁc for the p80 (E2) or Erns glycoproteins of BVDV may
have broad pestivirus speciﬁcity and may be unsuitable for the speciﬁc diagnosis of BD in sheep.
Virus-neutralisation assays provide an opportunity to control against misidentiﬁcation of BVDV-infected
animals by testing cross-neutralising of different strains or species of pestivirus. BDV-speciﬁc sera
should have a greater ability to neutralise BDV strains (a higher neutralising titre) than BVDV strains
(Dekker et al., 1995; Paton et al., 1995; Nettleton et al., 1998).
RT-PCR is now widely used for detection of pestivirus nucleic acid. While pan-pestivirus primers
may be used, they are not species-speciﬁc and a number of assays have been developed for speciﬁc
recognition of BD viruses (Fulton et al., 1999; McGoldrick et al., 1999; Vilbek and Paton, 2000). A
more recent multicolour real-time RT-PCR assay allows simultaneous detection and discrimination of
BDV and BVDV types 1 and 2 (Willoughby et al., 2006).
Control tools
Parameter 2 – Existence of control tools
With no commercially available and effective vaccine, disease outbreaks are generally controlled by
husbandry, with biosecurity measures similar to those in use for BVDV eradication (Nettleton, online).
In consultation with the veterinary surgeon, a ﬂock management programme should aim to remove all
PI animals from the ﬂock and prevent contact with or introduction of BDV-infected animals from
outside – particularly aimed at preventing infection of pregnant ewes. Testing should be an integral
part of this programme. Antibody ELISA on serum samples can be used to ascertain ﬂock status, as
ﬂocks containing congenitally infected animals will contain seropositive animals.
Importantly, seropositive animals are likely to be immune to further infection (with the same or
related virus strains (Dekker et al., 1995; Nettleton et al., 1998)). In contrast, BDV PI animals will be
antibody-negative but virus-positive and can be rapidly identiﬁed by antigen ELISA or PCR-based
testing (apart from about 2 months after colostrum with BDV-antibodies has been taken). Any virus
antigen-positive animals should be re-tested after at least 2 weeks to conﬁrm that the positive result
was not due to transient infection with BDV.
Table 1: ELISA kits for detection of BDV antibodies in sheep/goats
Company Base Test
LSI France LSIVetTM Ruminant BVD/BD p80 Serum/Milk ELISA Kit
Svanova Biotech AB Sweden SVANOVIR BDV-Ab kit
IDvet France ID Screen® BVD p80 Antibody One-Step
ID Screen® BVD p80 Antibody Competition
Hipra Spain CIVTEST BOVIS BVD/BD P80
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Important considerations for BDV control include:
• Maintenance of a closed ﬂock will help prevent disease as introduction of new stock is the
usual route of infection.
• Purchase only from ﬂocks free of BD and test all replacements for presence of virus.
• Isolate all newly purchased animals until they can be tested free of BDV. If testing is not done,
then this should include the separate mating of ewes and maintenance of separation until
lambing.
• If it is impractical to remove all PI sheep from the ﬂock, an alternative strategy would be to
deliberately expose the breeding stock to PI animals well in advance of the breeding season to
increase the level of ﬂock immunity. Indoor exposure for a period of weeks would be required
for increased infection levels (Nettleton, online).
Note that contact with BVDV-infected cattle could increase the possibility of infection with BVDV,
which can cause disease identical to BDV in sheep and goats and which can persist in a ﬂock or herd
in the same way. The converse is also true and BDV PI sheep or goats will present a risk of infection
to in-contact cattle (Sandvik, 2014).
An inactivated, combined vaccine against BDV and BVDV has been described (Brun et al., 1993) but
there is little evidence of its use or efﬁcacy in sheep, although BDV-speciﬁc neutralising antibodies
were demonstrated in cattle (Oguzoglu et al., 2003).
While there is clear need for a vaccine to prevent infection of pregnant susceptible sheep and
goats, the market for a BDV vaccine may not be sufﬁcient to support its development on economic
grounds. However, some diagnostic tests – both for antigen and antibody – do not clearly distinguish
between BVDV and BDV. Sheep and goats therefore could constitute a BDV reservoir such that BDV
infection of in-contact cattle may interfere with BVD status during eradication. Thus, the need to
prevent BDV infection interfering with BVDV eradication in cattle may provide further support for
development of a BDV vaccine (Sandvik, 2014).
3.1.2. Article 7(b) The impact of diseases
3.1.2.1. Article 7(b)(i) The impact of the disease on agricultural and aquaculture
production and other parts of the economy
The level of presence of the disease in the Union
Parameter 1 – Number of MSs where the disease is present
BDV infection has been reported in 11 MSs, although it is likely to be present in others MSs with
sufﬁcient numbers of sheep or goats that support the circulation of virus in the population. The
seroprevalence of infection can vary between countries and regions but may be in the range of 5-50%
among adult sheep (Nettleton et al., 1998; OIE, 2017). Published prevalence ﬁgures include 3% of
Austrian ﬂocks, with higher frequencies among animals on shared alpine pastures (Krametter-
Froetscher et al., 2007, 2010), 8% of Danish ﬂocks, 40–60% in alpine and Pyrenean chamois and
mouﬂon (Marco et al., 2009; Fernandez-Sirera et al., 2011, 2012a; Martin et al., 2011; Beaunee et al.,
2015), 46% of sheep ﬂocks in Ireland (O’Neill et al., 2004), about 27% of sheep and goat ﬂocks in the
Netherlands (Orsel et al., 2009), 30% of sheep ﬂocks in Northern Ireland (Graham et al., 2001), and
25–100% of Spanish sheep ﬂocks (Berriatua et al., 2004, 2006; Garcıa-Perez et al., 2010; Gonzalez
et al., 2014; Fernandez-Aguilar et al., 2016).
The loss of production due to the disease
Parameter 2 – Proportion of production losses (%) by epidemic/endemic situation
Infection of adult susceptible species with BDV usually leads to relatively mild symptoms, including
mild fever and leukopenia with a brief viraemia between days 4 and 11 post-infection, followed by
seroconversion producing virus neutralising antibodies that provide immunity to later infection with
similar strains of virus. However, one study has suggested that BDV infection causes economic losses
due to the increase in digestive and respiratory signs, together with the drop in growth rate and the
delayed slaughter in commercial conditions (Gonzalez et al., 2014).
Different strains of virus and infection of different hosts may also lead to different disease
outcomes, such as the large losses due to the Aveyron strain of BDV in sheep (Chappius et al., 1984)
and in outbreaks of BD in Pyrenean chamois (Marco et al., 2007).
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Infection of pregnant animals with BDV, particularly before the fetus becomes immunocompetent at
about day 85 of pregnancy, is an important cause of infertility in sheep, causing embryonic and fetal
death. Surviving lambs may be weak and have congenital abnormalities – especially of the nervous
system and coat. In goats, abortion is the most frequent outcome following infection of pregnant
females. In all susceptible species, the congenitally infected offspring that survive infection in utero are
the major source of infectious virus, which is shed from all secretions and excretions for the life of the
animal. Congenitally infected offspring may also be smaller and have poorer growth than uninfected
animals and have a shortened lifespan due to the activation of a cytopathic derivative of their infecting
virus.
The economic losses due to BDV are mainly the results of losses associated with increased
barrenness, abortion, stillbirth and neonatal death in the ﬂock. There are little data on the economic
impact but publications on losses in the UK (Sweasey et al., 1979; Sharp and Rawson, 1986)
suggested that losses due to BDV infection of pregnant ewes were due to both the reduction in the
number of surviving lambs and the reduced growth of surviving lambs, producing estimated losses of
20% and 45%, respectively, in the value of the lamb crop. The observed reduction on weight gain of
20% in a feedlot affected by transient BDV infection (Gonzalez et al., 2014) suggests that production
losses should not be attributed solely to infection of lambs in utero.
3.1.2.2. Article 7(b)(ii) The impact of the disease on human health
Not applicable – humans are not susceptible to infection with BDV.
3.1.2.3. Article 7(b)(iii) The impact of the disease on animal welfare
Parameter 1 – Severity of clinical signs at case level and related level and duration of impairment
In general, transient infection of sheep or goats with BDV is inapparent or leads to mild clinical
signs including fever, which are resolved within a few weeks. The main welfare issues associated with
BDV infection follow the infection of pregnant females, where a range of negative outcomes are
possible. These include resorption of pregnancy, abortion, stillbirth, and the birth of weak and PI
offspring. The main effect of BDV in goats is abortion, while PI sheep may show congenital
abnormalities, especially of the nervous system and coat.
However, more severe disease with increased morbidity and mortality has been observed in
outbreaks caused by speciﬁc BDV strains such as the Aveyron strain in sheep (Chappius et al., 1984;
Vega et al., 2015). Speciﬁc host–virus interactions may also have severe outcomes, including the
deaths among Pyrenean Chamois apparently caused by a BDV type 4 strain (Arnal et al., 2004; Marco
et al., 2007; Luzzago et al., 2016). In addition, it is possible that rearing conditions may impact on the
losses due to BD. A feedlot study of natural BDV infection showed more than half of the lambs tested
had BDV infection and these animals showed a 20% reduction in growth rate compared with
uninfected lambs at 3 months of age (Gonzalez et al., 2014).
In addition, congenitally PI lambs, born live, may also be smaller and have poorer growth than
uninfected animals and have a shortened lifespan, i.e. many may die at or around weaning and in
distinctive cases show tremor and abnormal body conformation and hairy ﬂeeces (Nettleton, online).
Those that survive to adulthood may die due to late onset of disease, with apparent similarities to
mucosal disease in cattle due to the activation of a cytopathic derivative of their infecting virus (Barlow
et al., 1983; Gardiner et al., 1983; Monies et al., 2004; Hilbe et al., 2009).
3.1.2.4. Article 7(b)(iv) The impact of the disease on biodiversity and the environment
Biodiversity
Parameter 1 – Endangered wild species affected: listed species as in CITES and/or IUCN list
It is likely that pestiviruses including BDV can infect a wide range of even-toed ungulates. This group
includes wild animals such as antelopes, camels, deer, giraffes, hippopotamuses, llamas and alpacas.
BDV infection has been demonstrated by serology or virus detection in several of these species:
Reindeer (Becher et al., 1999, 2003; Avalos-Ramirez et al., 2001), chamois (Arnal et al., 2004),
Pyrenean chamois, mouﬂon (Hemmatzadeh et al., 2016), alpaca and llama (Danuser et al., 2009).
Therefore, endangered potential hosts within Europe are those species classiﬁed in CITES
Appendix I (most endangered among CITES-listed animals) or II (potentially under threat), and
classed as potential BDV hosts on the basis of their species and geographic range (Table 2).
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Parameter 2 – Mortality in wild species
A number of wildlife species are potential hosts of BDV, as described above. The morbidity and
mortality among these species may be more severe than in domesticated hosts infected under
experimental conditions as a result of limited nutrition and concurrent infection (Arnal et al., 2004;
Fernandez-Sirera et al., 2012a). Indeed, among sheep, acute (transient) infection with BDV under
commercial feedlot conditions appeared to reduce growth rates (Gonzalez et al., 2014) compared with
experimental infection (Cabezon et al., 2010b).
Among those wildlife species that are known to be BDV hosts, mortality has only been described
for a few. In Pyrenean chamois, infection with BDV has been associated with signiﬁcant mortality
(Arnal et al., 2004) with potential inﬂuence on the population dynamics of this species (Cabezon et al.,
2011; Fernandez-Sirera et al., 2012a; Beaunee et al., 2015).
Environment
Parameter 3 – Capacity of the pathogen to persist in the environment and cause mortality in wildlife
BDV is rapidly inactivated by heat, drying, detergents and UV light. Recent studies suggest that
enveloped viruses may survive up to 5 days in dry environments (Firquet et al., 2015). Direct
transmission from PI to uninfected animals is considered the main route, so that spread within herds
of gathering animals may be more rapid than among solitary animal or between herds.
3.1.3. Article 7(c) Its potential to generate a crisis situation and its potential use
in bioterrorism
Parameter 1 – Listed in OIE/CFSPH classiﬁcation of pathogens
No – BDV is not listed among the ‘OIE-Listed diseases, infections and infestations in force in 2017’.
Further, it is not included in the Centre for Food Security and Public Health (CFSPH) list of Bioterrorism
and High Consequence Pathogen (CFSPH, 2017).
Parameter 2 – Listed in the Encyclopaedia of Bioterrorism Defence of Australia Group
No – BDV is not listed in the Australia Group List of Human and Animal Pathogens and Toxins for
Export Control (The Australia Group, 2017).
Parameter 3 – Included in any other list of potential bio- agro-terrorism agents
BDV is not included in the UK Approved List of biological agents produced by the Advisory
Committee on Dangerous Pathogens (HSE, 2013).
Table 2: List of endangered potential hosts for Border disease infection
Full Name English Names CITES Appendix
Bos mutus Wild yak I
Dama dama mesopotamica Mesopotamian fallow deer, Persian fallow deer I
Naemorhedus caudatus Chinese goral, long-tailed goral I
Oryx leucoryx Arabian oryx, white oryx I
Ovis aries ophion Cyprian wild sheep, Cyprus mouﬂon I
Ovis ammon Argali, Asian wild sheep, Marco Polo sheep I/II
Ovis aries Mouﬂon, red sheep, shapo, shapu, urial I/II
Ammotragus lervia Aoudad, barbary sheep, uaddan II
Capra caucasica West Caucasian tur II
Lama guanicoe Guanaco II
Moschus moschiferus Siberian musk deer II
Pecari tajacu Collared peccary II
Rupicapra pyrenaica ornata Abruzzo chamois, Apennine chamois II
Saiga tatarica Saiga, saiga antelope II
Tayassu pecari White-lipped peccary II
Saiga borealis Mongolian saiga II
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3.1.4. Article 7(d) The feasibility, availability and effectiveness of the following
disease prevention and control measures
3.1.4.1. Article 7(d)(i) Diagnostic tools and capacities
Availability
Parameter 1 – Ofﬁcially/internationally recognised diagnostic tool, OIE certiﬁed
The OIE Terrestrial Manual chapter on BD (OIE, 2017) lists the following tests for the detection of
BDV: virus isolation, immunohistochemistry for virus antigen, virus antigen ELISA, virus-speciﬁc
RT-PCR; and for detection of antibodies against BDV: virus-neutralisation test (VNT), ELISA and agar
gel immunodiffusion test. However, the choice of method will depend on the status of the animal to be
tested. PI animals will generally be virus-positive and antibody-negative throughout their lifetime. In
contrast, transiently infected animals will show a short viraemia for 1–2 weeks after BDV infection, and
will become BDV antibody-positive. The appropriate test for diagnosis will therefore depend on the test
aims (individual or herd status testing; identiﬁcation of PI animals) and the number and age of animals
to be tested.
Effectiveness
Parameter 2 – Se and Sp of diagnostic test
These data are not recorded for the tests listed in the IOE chapter on BDV (OIE, 2017) but some
commercial kits have recorded speciﬁcity and sensitivity data such as: Se 94% sheep, 100% goats; Sp
94% sheep, 100% goats (compared with VNT, SVANOVIR® BDV- Ab).
However, diagnostic speciﬁcity of many tests, both antibody and virus detection, may be
compromised by cross-reactivity between BDV and BVDV. Both antibody ELISA and PCR based testing
may include reagents that do not distinguish between these related viruses and care should be taken
to ensure that methods speciﬁc to BD are part of the diagnostic process. These include comparative
VNT (Nettleton et al., 1998) and multiplex RT-PCR (Willoughby et al., 2006).
Feasibility
Parameter 3 – Type of sample matrix to be tested (blood, tissue, etc.) (Table 3)
3.1.4.2. Article 7(d)(ii) Vaccination
There is no commercial vaccine for BDV, although some experimental work with an inactivated,
combined vaccine against BDV and BVDV has been described (Brun et al., 1993). Use of this vaccine in
sheep has not been reported but immunised cattle developed BDV-speciﬁc neutralising antibodies
(Oguzoglu et al., 2003). Vaccination of pregnant ewes with live and inactivated virus preparations
appeared to confer protection against subsequent challenge and reduced rates of infection in the
lambs being carried (Vantsis et al., 1980), suggesting that a BDV-speciﬁc vaccine for sheep is possible.
BVD eradication campaigns in several MSs may drive demand for a BDV vaccine to protect BVD-
negative cattle herds (Sandvik, 2014).
3.1.4.3. Article 7(d)(iii) Medical treatments
Not applicable – no speciﬁc drugs for treatment of BD are available.
Table 3: Types of sample matrix for different diagnostic tests
Test Suitable tissue(s)
Virus isolation Fresh blood or tissue
Immunohistochemistry for virus antigen Fixed/frozen tissue
Virus antigen ELISA Blood, fresh or ﬁxed tissue
Virus-speciﬁc RT-PCR Blood, fresh or ﬁxed tissue
Virus neutralisation test Blood serum or plasma
ELISA Blood serum or plasma
Agar gel immunodiffusion test Blood serum or plasma
ELISA: enzyme-linked immunosorbent assay; RT-PCR: reverse-transcription polymerase chain reaction.
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3.1.4.4. Article 7(d)(iv) Biosecurity measures
Availability
Parameter 1 – Available biosecurity measures
Biosecurity for BD should be aimed at preventing infection, particularly of pregnant animals, by the
operation of a closed ﬂock with appropriate testing and separation of bought-in stock.
Important considerations for BDV control include:
• A major risk of infection comes from the movement or purchase of animals that may be
shedding BDV due to transient or persistent infection. Care should therefore be taken following
the purchase of new stock or the return of animals from communal grazing or other events.
• All new stock or animals which have been away from the farm should be quarantined until
they can be tested.
• Appropriate diagnostic tests for BDV infection should be performed on all quarantined animals
to demonstrate freedom from BDV before mixing with other stock. Detection of BDV nucleic
acid or antigen will identify infected animals and two positive tests, separated by at least
4 weeks, will identify PI animals that should be culled. A positive serological test result shows
that an animal has been transiently infected and is unlikely to be shedding virus (except for
lambs of less than 2 months old which may have maternally derived antibodies).
• Infectious material can be carried on bedding, clothes, boots and equipment. Practise good
hygiene, including the use of effective disinfectants, particularly when moving between
quarantined animals and other stock.
• Consult with a veterinary surgeon on a herd/ﬂock health plan in order to minimise infection.
Effectiveness
Parameter 2 – Effectiveness of biosecurity measures in preventing the pathogen introduction
As the most important source of BDV for uninfected farms is the introduction of PI animals,
properly executed biosecurity should be highly effective. The virus spreads best in enclosed spaces
such as shared accommodation and has also been documented to spread on communal pastures, so
the enforcement of appropriate biosecurity should remove the opportunity for susceptible animals to
mix with potentially infected individuals.
Feasibility
Parameter 3 – Feasibility of biosecurity measures
This depends of the individual business and its ability to operate without mixing its stock with new
purchases or animals from other farms. Ideally, this approach to disease prevention should be feasible
and simple to adopt.
3.1.4.5. Article 7(d)(v) Restrictions on the movement of animals and products
Availability
Parameter 1 – Available movement restriction measures
BDV is not controlled at EU level, so there are no formal movement restriction measures in place. While
eradication of the related BVDV is complete in Scandinavia and Switzerland, national or regional BVD
eradication programmes are in place in Austria, the Netherlands, Germany, Scotland, Ireland, and regions
of France and Italy, with herd-based schemes in England, France, Italy Spain and Portugal (BVDzero, 2017).
In those EU MSs which become free of BVDV, the problems of diagnostic cross-reactivity with BD infection
could be a reason for introduction of controls (Braun et al., 2013; Sandvik, 2014; Kaiser et al., 2017).
Effectiveness
Parameter 2 – Effectiveness of restriction of animal movement in preventing the between farm spread
The main mode of infection appears to be through close contact, with a lower component of
spread via aerosols or fomites (Nettleton et al., 1998; Krametter-Froetscher et al., 2007; Braun et al.,
2013; OIE, 2017). It is therefore likely that the restrictions on the movement of PI animals off farms
would be an effective means of reducing spread of BDV in the same manner as this, coupled with
effective diagnostic testing, has been demonstrated effective for BVDV control.
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Feasibility
Parameter 3 – Feasibility of restriction of animal movement
Effective restriction would need to be applied only to PI animals, which would be virus-positive in
two tests separated by at least 4 weeks. Therefore, any application of movement restriction would
need to be accompanied by suitable screening to identify the animals that were the source of infection
in the same manner as this has been demonstrated effective for BVDV control.
3.1.4.6. Article 7(d)(vi) Killing of animals
Availability
Parameter 1 – Available methods for killing animals
EU MSs are required to have animal killing capability as part of measures for control of exotic
disease incursions. Available measures and associated procedures to assure animal protection are
detailed in Council Regulation (EC) No 1099/20091.
Effectiveness
Parameter 2 – Effectiveness of killing animals (at farm level or within the farm) for reducing/stopping
spread of the disease
The identiﬁcation and slaughter of PI animals at an early age would be the single most effective
measure for the eradication of BDV from MSs. However, the lack of clear clinical signs in infected
animals means that sensitive and speciﬁc diagnosis of BDV infection would be required.
Feasibility
Parameter 3 – Feasibility of killing animals
The number of PI animals in any outbreak of BDV appears to be 1% or less of the total at-risk population
(Krametter-Froetscher et al., 2010; Schweizer and Peterhans, 2014). Removal of this number of animals is
therefore feasible within the context of a national/international testing and disease eradication scheme.
3.1.4.7. Article 7(d)(vii) Disposal of carcasses and other relevant animal by-products
Availability
Parameter 1 – Available disposal option
Disposal options for sheep and goat carcases and associated wastes are: commercial ﬁxed plant
incineration; rendering; commercial landﬁll sites (with appropriate approval).
Effectiveness
Parameter 2 – Effectiveness of disposal option
Incineration and rendering would effectively inactivate BDV. Use of landﬁll may also be effective as
BDV is likely to be inactivated rapidly.
Feasibility
Parameter 3 – Feasibility of disposal option
Given the relatively small numbers involved, carcase disposal is likely to be feasible.
3.1.5. Article 7(e) The impact of disease prevention and control measures
3.1.5.1. Article 7(e)(i) The direct and indirect costs for the affected sectors and the
economy as a whole
Parameter 1 – Cost of control (e.g. treatment/vaccine, biosecurity)
Vaccine to prevent the infection of pregnant ewes would be desirable but may not be perceived as
cost-effective by the vaccine developing industry. In the absence of licensed treatments or vaccines for
1 Council Regulation (EC) No 1099/2009 of 24 September 2009 on the protection of animals at the time of killing. J L 303,
18.11.2009, p. 1–30.
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BDV infection, appropriate biosecurity to prevent infection by external contacts such as newly
purchased or returning animals remains the most important means. This includes the identiﬁcation of
infected ﬂocks where BDV is circulating and then identiﬁcation and removal of all PI animals. The cost-
effectiveness of this measure would be greater in higher than in lower prevalence countries and would
depend on the structure of the industry relevant to biosecurity. The main aim of such measures should
be to avoid infection of pregnant ewes and the prompt removal of PI animals. Diagnostic testing
should be an integral part of this programme.
As no organised plans for testing sheep for BDV seem to have been presented with the aim to
reduce the prevalence of the infection, an estimate of the costs of such measures is difﬁcult to
separate from the costs of eradication (below) as the same approaches would be used. However, the
recognition that BD viruses in sheep and cattle can potentially interfere with national plans to eradicate
BVDV in cattle has stimulated renewed interest in BD and its control (Sandvik, 2014).
Parameter 2 – Cost of eradication (culling, compensation)
An estimate of the costs of such measures is difﬁcult to separate from the costs of control as the
same approaches would be used (see Parameter 1 above).
Across EU MSs, the numbers of sheep and goats total over 85 and 12 millions, respectively. If we
estimate the range of prevalence to be 5–50% (OIE, 2017) and the presence of PI animals at 1% of
affected animals (Schweizer and Peterhans, 2014), then the estimated numbers of PI animals in EU
MSs will be 42,000–420,000 sheep and 6,250–62,500 goats, with estimated values of EUR 2–20 M
(sheep) and EUR 0.15–1.5 M (goats) (Eurostat, 2017).
It is likely that these costs (EUR 25–250,000 per million sheep and EUR 12.5000–125,000 per
million goats) provide a reasonable estimate of potential culling and compensation costs to remove PI
animals from all MSs.
Parameter 3 – Cost of surveillance and monitoring
These costs are harder to estimate as it is likely that all ﬂocks and herds would need to be initially
screened to determine what herds had circulating BDV in the herd causing BDV-speciﬁc antibody levels
in the most recent lamb crop (bulk testing for BDV-speciﬁc antibody), followed by sampling of all
animals in positive ﬂocks including testing of individual seronegative animals for the presence of
antigen (antigen ELISA or RT-PCR), suggesting that the costs could be high depending on the BDV
herd prevalence.
Parameter 4 – Trade loss (bans, embargoes, sanctions) by animal product
BDV is not notiﬁable and there are no ofﬁcial controls at EU level. However, it is possible that MSs
with BVDV eradication programmes may implement controls to protect BVDV-free cattle herds from BDV.
Parameter 5 – Importance of the disease for the affected sector (% loss or € lost compared to
business amount of the sector)
BD often goes unnoticed as its effects are mainly on fertility, rather than morbidity in older animals,
and poor scanning rates for pregnancy and losses due to abortion, stillbirth, or neonatal deaths may
not immediately be ascribed to BD. Indeed, among sheep, BDV is not perceived as a major cause of
abortion (Mearns, 2007). However, its impact may be underestimated.
3.1.5.2. Article 7(e)(ii) The societal acceptance of disease prevention and control
measures
There are no speciﬁc studies on BDV. It is anticipated that any improvement in the BDV status of
sheep and goats will be socially well received as the immediate results of eradication would be a
reduction in the numbers of lambs/kids lost due to this disease, improving animal welfare and industry
proﬁtability.
3.1.5.3. Article 7(e)(iii) The welfare of affected subpopulations of kept and wild animals
Parameter 1 – Welfare impact of control measures on domestic animals
Imposing movement restrictions on infected premises, pending the identiﬁcation and removal of all
PIs, would have an impact on the industry through an inability to sell stock, particularly if restrictions
coincide with annual lamb sales. However, there are unlikely to be speciﬁc welfare consequences of
such restrictions. Compulsory culling of PI animals would have negative welfare impact on the
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proportion of such animals being culled that would otherwise survive healthy and not succumb to BDV,
due to the activation of a cytopathic derivative of their infecting virus, but the potential reduction in
morbidity associated with transient infection would have welfare beneﬁts for uninfected ﬂocks.
Parameter 2 – Wildlife depopulation as control measure
There are few species that carry BDV at a sufﬁciently high frequency to justify such measures. The
contacts between domestic sheep and goats are more likely to lead to infection of the wildlife species
and would only be an issue at late stages in BDV eradication, where potential reservoirs of infection in
wildlife may need to be considered.
3.1.5.4. Article 7(e)(iv) The environment and biodiversity
Environment
Parameter 1 – Use and potential residuals of biocides or medical drugs in environmental compartments
(soil, water, feed, manure)
There are currently no biocides or medical drugs available for use with BDV.
Biodiversity
Parameter 2 – Mortality in wild species
A few reports have suggested that wildlife species such as the Pyrenean chamois suffer
considerable mortality as a consequence of BDV infection (Arnal et al., 2004; Marco et al., 2015;
Serrano et al., 2015). Morbidity and mortality were replicated in an experimental infection of chamois
(Cabezon et al., 2011), but not of sheep (Cabezon et al., 2010b) or pigs (Cabezon et al., 2010a). It is
therefore possible that morbidity and mortality resulting from BDV infection of wildlife species may
depend on either circulation of species-speciﬁc strains or the movement of novel virus strains into a
susceptible population by interspecies infection. Further research is therefore required to study the
distribution of BDV strains in wildlife species.
3.2. Assessment according to Article 5 criteria
This section presents the results of the expert judgement on the criteria of Article 5 of the AHL
about BD (Table 4). The expert judgement was based on Individual and Collective Behavioural
Aggregation (ICBA) approach described in detail in the opinion on the methodology (EFSA AHAW
Panel, 2017). Experts have been provided with information of the disease fact-sheet mapped into
Article 5 criteria (see supporting information, Annex A), based on that the experts indicate their Y/N or
‘na’ judgement on each criterion of Article 5, and the reasoning supporting their judgement.
The minimum number of judges in the judgement was 12. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation
of the questions, see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
Table 4: Outcome of the expert judgement on the Article 5 criteria for Border disease
Criteria to be met by the disease:
According to AHL, a disease shall be included in the list referred to in point (b) of paragraph 1 of
Article 5 if it has been assessed in accordance with Article 7 and meets all of the following criteria
Final
outcome
A(i) The disease is transmissible Y
A(ii) Animal species are either susceptible to the disease or vectors and reservoirs thereof exist in
the Union
Y
A(iii) The disease causes negative effects on animal health or poses a risk to public health due to
its zoonotic character
Y
A(iv) Diagnostic tools are available for the disease Y
A(v) Risk-mitigating measures and, where relevant, surveillance of the disease are effective and
proportionate to the risks posed by the disease in the Union
Y
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3.2.1. Non-consensus questions
This section displays the assessment related to each criterion of Article 5 where no consensus was
achieved in form of tables (Tables 5 and 6). The proportion of Y, N or na answers is reported, followed
by the list of different supporting views for each answer.
Reasoning supporting the judgement
Supporting Yes:
• An experimental study showed that a large proportion (55%) of BDV-infected lambs had 2.1
times higher risk of showing gastrointestinal and respiratory signs of disease and showed a
20% reduction in growth rate compared to uninfected lambs (Gonzalez et al., 2014). Infection
before the onset of fetal immunocompetence causes approximately 50% fetal death, with
surviving lambs being congenitally infected. In addition, more severe forms of the disease in
the case of highly pathogenic strains of BDV could occur, e.g. Aveyron strain producing
outbreaks with mortality of 70% or more in sheep and production loss (20–45%) in UK. BDV
infection has been reported in 11 MSs.
• BDV infection is similar to the infection caused by BVDV. Limited data are available compared
to BVD, nonetheless reports do indicate that the infection could cause signiﬁcant losses.
Supporting na:
• Data on economic impact in natural infections are scarce.
At least one criterion to be met by the disease:
In addition to the criteria set out above at points A(i)–A(v), the disease needs to fulﬁl at least one of the
following criteria
B(i) The disease causes or could cause signiﬁcant negative effects in the Union on animal health,
or poses or could pose a signiﬁcant risk to public health due to its zoonotic character
Y
B(ii) The disease agent has developed resistance to treatments and poses a signiﬁcant danger to
public and/or animal health in the Union
na
B(iii) The disease causes or could cause a signiﬁcant negative economic impact affecting
agriculture or aquaculture production in the Union
NC
B(iv) The disease has the potential to generate a crisis or the disease agent could be used for the
purpose of bioterrorism
N
B(v) The disease has or could have a signiﬁcant negative impact on the environment, including
biodiversity, of the Union
NC
Colour code: green = consensus (Yes/No), yellow = non-consensus (NC), red = not applicable (na), i.e. insufﬁcient evidence or
irrelevant to judge.
Table 5: Outcome of the expert judgement related to criterion 5 B(iii)
Question
Final
outcome
Response
Y (%) N (%) na (%)
B(iii) The disease causes or could cause a signiﬁcant negative
economic impact affecting agriculture or aquaculture
production in the Union
NC 92 0 8
NC: non-consensus; number of judges: 12.
Table 6: Outcome of the expert judgement related to criterion 5 B(v)
Question
Final
outcome
Response
Y (%) N (%) na (%)
B(v) The disease has or could have a signiﬁcant negative impact
on the environment, including biodiversity, of the Union
NC 67 33 0
NC: non-consensus; number of judges: 12.
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Reasoning supporting the judgement
Supporting Yes:
• EU wildlife species such as the Pyrenean chamois (not endangered) and, at a lesser degree,
Cyprus mouﬂon, Apennine chamois and mouﬂon (endangered) are concerned by BDV infection
and could suffer with considerable level of mortality as a consequence of BDV infection. In
Pyrenean chamois, infection with BDV has been associated with signiﬁcant mortality (Arnal
et al., 2004) with potential inﬂuence on the population dynamics of this species (Cabezon
et al., 2011; Fernandez-Sirera et al., 2012a; Beaunee et al., 2015).
Supporting No:
• The disease has been reported to cause signiﬁcant mortality in chamois, but at the same time
many infected populations of chamois remain unaffected.
• The infection has been detected in wild ruminant populations and in no case after introduction
of BDV has there been a description of total population collapse.
3.2.2. Outcome of the assessment of Border disease according to criteria of
Article 5(3) of the AHL on its eligibility to be listed
As from the legal text of the AHL, a disease is considered eligible to be listed as laid down in Article
5 if it fulﬁls all criteria of the ﬁrst set from A(i) to A(v) and at least one of the second set of criteria
from B(i) to B(v). According to the assessment methodology (EFSA AHAW Panel, 2017), a criterion is
considered fulﬁlled when the outcome is ‘Yes’. According to the results shown in Table 4, BD disease
complies with all criteria of the ﬁrst set and with one criterion of the second set, therefore it is
considered eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL.
3.3. Assessment according to Article 9 criteria
This section presents the results of the expert judgement on the criteria of Annex IV referring to
categories as in Article 9 of the AHL about BD (Tables 7, 8, 9, 10 and 11). The expert judgement was
based on ICBA approach described in detail in the opinion on the methodology. Experts have been
provided with information of the disease fact-sheet mapped into Article 9 criteria (see supporting
information, Annex A), based on that the experts indicate their Y/N or ‘na’ judgement on each criterion
of Article 9, and the reasoning supporting their judgement.
The minimum number of judges in the judgement was 12. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation
of the questions see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
Table 7: Outcome of the expert judgement related to the criteria of Section 1 of Annex IV
(category A of Article 9) for Border disease (CI: current impact; PI: potential impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is not present in the territory of the Union OR present only in exceptional
cases (irregular introductions) OR present only in a very limited part of the territory of the
Union
N
2.1 The disease is highly transmissible N
2.2 There are possibilities of airborne or waterborne or vector-borne spread N
2.3 The disease affects multiple species of kept and wild animals OR single species of kept
animals of economic importance
Y
2.4 The disease may result in high morbidity and signiﬁcant mortality rates NC
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic or pandemic potential OR possible signiﬁcant threats to food safety
N
4(CI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
NC
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4(PI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
Y
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour markets N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour markets N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
NC
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
Y
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
Y
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term
damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term
damage to those species or breeds
Y
Colour code: green = consensus (Yes/No), yellow = non-consensus (NC).
Table 8: Outcome of the expert judgement related to the criteria of Section 2 of Annex IV
(category B of Article 9) for Border disease (CI: current impact; PI: potential impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic
character AND (at the same time) several Member States or zones of the Union are free of
the disease
N
2.1 The disease is moderately to highly transmissible Y
2.2 There are possibilities of airborne or waterborne or vector-borne spread N
2.3 The disease affects single or multiple species Y
2.4 The disease may result in high morbidity with in general low mortality NC
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic potential OR possible signiﬁcant threats to food safety
N
4(CI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
NC
4(PI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
Y
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour markets N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour markets N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
NC
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
Y
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
Y
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term
damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term
damage to those species or breeds
Y
Colour code: green = consensus (Yes/No), yellow = non-consensus (NC).
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Table 9: Outcome of the expert judgement related to the criteria of Section 3 of Annex IV
(category C of Article 9) for Border disease (CI: current impact; PI: potential impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic character Y
2.1 The disease is moderately to highly transmissible Y
2.2 The disease is transmitted mainly by direct or indirect transmission Y
2.3 The disease affects single or multiple species Y
2.4 The disease usually does not result in high morbidity and has negligible or no mortality
AND often the most observed effect of the disease is production loss
Y
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health, or
possible signiﬁcant threats to food safety
N
4(CI) The disease has a signiﬁcant impact on the economy of parts of the Union, mainly related
to its direct impact on certain types of animal production systems
NC
4(PI) The disease has a signiﬁcant impact on the economy of parts of the Union, mainly related
to its direct impact on certain types of animal production systems
N
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour markets N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour markets N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
NC
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
Y
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
Y
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term
damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term
damage to those species or breeds
Y
Colour code: green = consensus (Yes/No), yellow = non-consensus (NC).
Table 10: Outcome of the expert judgement related to the criteria of Section 4 of Annex IV
(category D of Article 9) for Border disease
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
D The risk posed by the disease in question can be effectively and proportionately mitigated by
measures concerning movements of animals and products in order to prevent or limit its
occurrence and spread
Y
The disease fulﬁls criteria of Sections 1, 2, 3 or 5 of Annex IV of AHL Y
Colour code: green = consensus (Yes/No).
Table 11: Outcome of the expert judgement related to the criteria of Section 5 of Annex IV
(category E of Article 9) for Border disease
Diseases in category E need to fulﬁl criteria of Sections 1, 2 or 3 of Annex IV of AHL and/or
the following:
Final
outcome
E Surveillance of the disease is necessary for reasons relating to animal health, animal welfare,
human health, the economy, society or the environment (If a disease fulﬁls the criteria as in
Article 5, thus being eligible to be listed, consequently category E would apply.)
Y
Colour code: green = consensus (Yes/No).
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3.3.1. Non-consensus questions
This section displays the assessment related to each criterion of Annex IV referring to the
categories of Article 9 of the AHL where no consensus was achieved in form of tables (Tables 12, 13
and 14). The proportion of Y, N or ‘na’ answers are reported, followed by the list of different
supporting views for each answer.
Reasoning supporting the judgement
Supporting Yes for 2.4 (cat. A):
• Highly pathogenic strain (e.g. Aveyron) causes severe forms with high morbidity and high
mortality.
• Overall individual seroprevalence can vary between 5% and 50%. There may be high mortality
if impact on offspring (e.g. in PI) is considered and high morbidity in surviving lambs, whereas
mortality in adults is generally low.
• There could be either high or low mortality, depending on if infected and immunocompetent
(mostly with short and unapparent disease) are included among the morbid animals.
• Depending on how fetal mortality is characterised, i.e. mortality (cat. A) or production loss
(cat. C) can apply.
Supporting Yes for 2.4 (cat. B):
• Depending on husbandry and other factors there may be high morbidity with generally low
mortality.
• Prevalence can be up to 100%, but mortality rates remain low.
Reasoning supporting the judgement
Supporting No for 4 (cat. A, B):
• Although the impact at farm level might be signiﬁcant, there are no reports documenting the
impact at country level and no current control programme suggesting that the disease
currently does have a signiﬁcant impact on the economy of the Union.
Table 12: Outcome of the expert judgement related to criterion 2.4 of Article 9
Question
Final
outcome
Response
Y (%) N (%) na (%)
2.4 (cat. A) The disease may result in high morbidity and signiﬁcant
mortality rates
NC 67 33 0
2.4 (cat. B) The disease may result in high morbidity with in general
low mortality
NC 83 17 0
NC: non-consensus; number of judges: 12.
Table 13: Outcome of the expert judgement related to criterion 4(CI) of Article 9
Question
Final
outcome
Response
Y (%) N (%) na (%)
4 (cat. A, B) The disease has a signiﬁcant impact on the
economy of the Union, causing substantial costs,
mainly related to its direct impact on the health
and productivity of animals
NC 0 83 17
4 (cat. C) The disease has a signiﬁcant impact on the
economy of parts of the Union, mainly related to
its direct impact on certain types of animal
production systems
NC 0 92 8
NC: non-consensus; number of judges: 12.
AHL assessment on Border disease
www.efsa.europa.eu/efsajournal 22 EFSA Journal 2017;15(10):4993
Supporting na for 4 (cat. A, B):
• It depends on the strain. Solid data on the economic impact of BDV in MSs are very limited, no
effective vaccines and no control programmes have been developed suggesting that the
economic impact is probably perceived as quite limited. Sheep production contributes
differently to the economy in different countries. No information is available about impact or
distribution.
Supporting No for 4 (cat. C):
• Although the impact of BD is likely greater in intensive sheep production, there is not any
particular production system affected.
• There are consequences in animal health and production, but not to a level that impacts the
economy of the Union.
Supporting na for 4 (cat. C):
• Data on economic impact are very limited.
Reasoning supporting the judgement
Supporting Yes:
• Lambs born with BDV congenital infection can be underweight and weak. In distinctive cases
lambs show tremor, abnormal body conformation and hairy ﬂeeces (Nettleton, online).
• The welfare of PI would be greatly comprised: 1% PI of at-risk animals represents a large
number.
Supporting No:
• Abortions and production loss are not considered per se as welfare impairment, and if present
clinical signs in the dam are weak.
Supporting na:
• There are insufﬁcient data quantifying the numbers with welfare effects caused by BDV.
3.3.2. Outcome of the assessment of criteria in Annex IV for Border disease for
the purpose of categorisation as in Article 9 of the AHL
As from the legal text of the AHL, a disease is considered ﬁtting in a certain category (A, B, C, D or
E corresponding to point (a) to point (e) of Article 9(1) of the AHL) if it is eligible to be listed for Union
intervention as laid down in Article 5(3) and fulﬁls all criteria of the ﬁrst set from 1 to 2.4 and at least
one of the second set of criteria from 3 to 5(d) as shown in Tables 7–11. According to the assessment
methodology (EFSA AHAW Panel, 2017), a criterion is considered fulﬁlled when the outcome is ‘Yes’.
With respect to different type of impact where the assessment is divided into current and potential
impact, a criterion will be considered fulﬁlled if at least one of the two outcomes is ‘Y’ and, in case of
no ‘Y’, the assessment is inconclusive if at least one outcome is ‘NC’.
A description of the outcome of the assessment of criteria in Annex IV for BD for the purpose of
categorisation as in Article 9 of the AHL is presented in Table 15.
Table 14: Outcome of the expert judgement related to criterion 5(b)(CI) of Article 9
Question
Final
outcome
Response
Y (%) N (%) na (%)
5b The disease has a signiﬁcant impact on animal welfare, by
causing suffering of large numbers of animals
NC 42 33 25
NC: non-consensus; number of judges: 12.
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According to the assessment here performed, BD complies with the following criteria of the
Sections 1 to 5 of Annex IV of the AHL for the application of the disease prevention and control rules
referred to in points (a) to (e) of Article 9(1):
1) To be assigned to category A, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment BD complies with criterion 2.3, but not with
criteria 1, 2.1 and 2.2 and the assessment is inconclusive on compliance with criterion 2.4.
To be eligible for category A, a disease needs to comply additionally with one of the criteria
of the second set (3, 4, 5a–d) and BD complies with criteria 4, 5b, 5c and 5d, but not with
criteria 3 and 5a.
2) To be assigned to category B, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment BD complies with criteria 2.1 and 2.3, but not
with criteria 1 and 2.2 and the assessment is inconclusive on compliance with criterion 2.4.
To be eligible for category B, a disease needs to comply additionally with one of the criteria
of the second set (3, 4, 5a–d) and BD complies with criteria 4, 5b, 5c and 5d, but not with
criteria 3 and 5a.
3) To be assigned to category C, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment BD complies with all of them. To be eligible for
category C, a disease needs to comply additionally with one of the criteria of the second set
(3, 4, 5a–d) and BD complies with criteria 5b, 5c and 5d, but not with criteria 3 and 5a and
the assessment is inconclusive on compliance with criterion 4.
4) To be assigned to category D, a disease needs to comply with criteria of Sections 1, 2, 3 or 5
of Annex IV of the AHL and with the speciﬁc criterion D of Section 4, with which BD
complies.
5) To be assigned to category E, a disease needs to comply with criteria of Sections 1, 2 or 3 of
Annex IV of the AHL and/or the surveillance of the disease is necessary for reasons relating
to animal health, animal welfare, human health, the economy, society or the environment.
The latter is applicable if a disease fulﬁls the criteria as in Article 5, with which BD complies.
3.4. Assessment of Article 8
This section presents the results of the assessment on the criteria of Article 8(3) of the AHL about
BD. The Article 8(3) criteria are about animal species to be listed, as it reads below:
‘3. Animal species or groups of animal species shall be added to this list if they are affected or if
they pose a risk for the spread of a speciﬁc listed disease because:
a) they are susceptible for a speciﬁc listed disease or scientiﬁc evidence indicates that such
susceptibility is likely; or
Table 15: Outcome of the assessment of criteria in Annex IV for Border disease for the purpose of
categorisation as in Article 9 of the AHL
Category
Article 9 criteria
1° set of criteria 2° set of criteria
1 2.1 2.2 2.3 2.4 3 4 5a 5b 5c 5d
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b) they are vector species or reservoirs for that disease, or scientiﬁc evidence indicates that such
role is likely’.
For this reason, the assessment on Article 8 criteria is based on the evidence as extrapolated from
the relevant criteria of Article 7, i.e. the ones related to susceptible and reservoir species or routes of
transmission, which cover also possible role of biological or mechanical vectors.2 According to the
mapping, as presented in Table 5, Section 3.2 of the scientiﬁc opinion on the ad hoc methodology
(EFSA AHAW Panel, 2017), the main animal species to be listed for BD according to the criteria of
Article 8(3) of the AHL are as displayed in Table 16.
4. Conclusions
TOR 1: for each of those diseases an assessment, following the criteria laid down in Article 7 of
the AHL, on its eligibility of being listed for Union intervention as laid down in Article 5(3) of the AHL;
• According to the assessment here performed, BD complies with all criteria of the ﬁrst set and
with one criterion of the second set and therefore can be considered eligible to be listed for
Union intervention as laid down in Article 5(3) of the AHL.
TOR 2a: for each of the diseases which was found eligible to be listed for Union intervention, an
assessment of its compliance with each of the criteria in Annex IV to the AHL for the purpose of
categorisation of diseases in accordance with Article 9 of the AHL;
• According to the assessment here performed, BD meets the criteria as in Sections 3, 4 and 5
of Annex IV of the AHL, for the application of the disease prevention and control rules referred
to in points (c), (d) and (e) of Article 9(1) of the AHL.
TOR 2b: for each of the diseases which was found eligible to be listed for Union intervention, a list of
animal species that should be considered candidates for listing in accordance with Article 8 of the AHL.
• According to the assessment here performed, the animal species that can be considered to be
listed for BD according to Article 8(3) of the AHL are mainly sheep and other species of the
family Bovidae as susceptible and reservoirs, as reported in Table 16 in Section 3.4 of the
present document.
Table 16: Main animal species to be listed for Border disease according to criteria of Article 8
(source: data reported in Section 3.1.1.1)
Class Order Family Genus/Species
Susceptible Mammalia Artiodactyla Bovidae Sheep (Ovis aries), cattle (Bos taurus, Bos
indicus), goats (Capra hircus), chamois
(Rupicapra rupicapra), Pyrenean chamois
(Rupicapra pyrenaica pyrenaica), mouﬂon
(Ovis orientalis), Alpine ibex (Capra ibex),
antelopes (not speciﬁed)
Suidae Pig (Sus scrofa)
Camelidae Alpaca (Vicugna pacos), llama (Lama glama)
Cervidae Reindeer (Rangifer tarandus)
Girafﬁdae not speciﬁed
Hippopotamidae not speciﬁed
Lagomorpha Leporidae European hare (Lepus europaeus)
Reservoir Mammalia Artiodactyla Bovidae Sheep (Ovis aries), cattle (Bos taurus, Bos
indicus), goats (Capra hircus)
Suidae Pig (Sus scrofa)
Vectors none
2 A vector is a living organism that transmits an infectious agent from an infected animal to a human or another animal. Vectors
are frequently arthropods. Biological vectors may carry pathogens that can multiply within their bodies and be delivered to new
hosts, usually by biting. In mechanical vectors, the pathogens do not multiply within the vector, which usually remains infected
for shorter time than in biological vectors.
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Abbreviations
AHAW EFSA Panel on Animal Health and Welfare
AHL Animal Health Law
BD Border disease
BDV Border disease virus
BVDV bovine viral diarrhoea virus
CFSPH Centre for Food Security and Public Health
CSFV classical swine fever virus
ELISA enzyme-linked immunosorbent assay
ICBA Individual and Collective Behavioural Aggregation
MS Member State
OIE World Organization for Animal Health
PI persistently infected
RT-PCR reverse-transcription polymerase chain reaction
TI transiently infected
ToR Terms of Reference
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VNT virus-neutralisation test
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Annex A – Mapped fact-sheet used in the individual judgement on Border
disease
Annex A can be found in the online version of this output (‘Supporting information’ section):
https://doi.org/10.2903/j.efsa.2017.4993
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